Fractyl Health (GUTS)
Develops clinical-stage therapies for obesity and type 2 diabetes through the gut and pancreas.
Something off on this page? Send us feedback.
Develops Revita, a procedure in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV gene-therapy platform. Both programs remain clinical-stage and depend on clinical evidence and regulatory pathways.
Develops Revita, a single-procedure therapy in pivotal development for post-GLP-1 weight maintenance. The company describes it as the procedural arm of its obesity portfolio.
Rejuva is the AAV gene-therapy arm. Its lead candidate, RJVA-001, is planned for a first-in-human study in adults with inadequately controlled T2D, subject to site activation.
Headquartered in Burlington, Massachusetts, the founder-led organization has 100 full-time employees, most dedicated to research and development. It operates as a single segment rather than commercial business lines; clinical evidence and regulatory pathways for both programs shape the business at this stage.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 1, 2026 | Craig-Hallum | Initiate | Rating: — | |
| Jan 30, 2026 | Morgan Stanley | Downgrade | ||
| Jan 29, 2026 | Morgan Stanley | Target | Target: — | Target: $2 |
| Dec 19, 2025 | Canaccord Genuity | Target | Target: — | Target: $8 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $47.1M · Total debt $60.7M · Total assets $82.0M · Shareholders' equity −$1.7M
- Revenue
- $0
- Operating income
- −$19.1M
- Net income
- −$25.5M
No dividends on record.
| Institutions | 44.50% | 70.83M shares | |
|---|---|---|---|
| 76 holders · as of Jun 30, 2026 | |||
| Insiders | 5.13% | 8.17M shares | |
| 9 holders · as of Sep 16, 2026 | |||
| Other | 50.37% | 80.18M shares | |
| remainder | |||
159.18M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Nantahala Capital Management, LLCInstitution | 7.09% | 11.29M | as of Jun 30, 2026 |
Ajay RoyanInsiderdirector | 4.05% | 6.45M | filed Jun 15, 2026 |
Catalio Capital Management, LPInstitution | 3.88% | 6.17M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.83% | 6.10M | as of Jun 30, 2026 |
Bank of America Corp /DE/Institution | 3.79% | 6.03M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | William Bradley | director | +64,516 | $0.6185 |
| Jun 12, 2026 | Ajay Royan | director | +23,000 | $0.8520 |
| Jun 10, 2026 | Harith Rajagopalan | director, officer: Chief Executive Officer | +25,000 | $0.7301 |
| Jun 10, 2026 | Ian Sheffield | director | +35,000 | $0.7294 |
| Jun 10, 2026 | William Bradley | director | +68,493 | $0.7348 |
- Eli Lilly
Tirzepatide therapies for obesity and type 2 diabetes
- Novo Nordisk (ADR)
Semaglutide therapies for obesity and type 2 diabetes
- Amgen
MariTide Phase 3 program spans obesity and T2D
- Viking Therapeutics
VK2735 Phase 3 obesity program includes adults with T2D
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Fractyl Health | $0.4821 | −12.82% | $87.7M | — | — | — | — |
| Eli Lilly | $1,152.29 | −1.53% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Novo Nordisk (ADR) | $38.23 | −2.98% | $174.96B | 9.9 | 15.8 | 3.5 | +1.3% |
| Amgen | $406.73 | −0.86% | $221.41B | 25.5 | 17.3 | 5.8 | +9.7% |
| Viking Therapeutics | $40.97 | +0.28% | $4.77B | — | — | — | — |
| Median | 25.5 | 17.3 | 5.8 | +9.7% |